Procedures
Prior to commencing treatment, baseline assessments were performed, including sociodemographic data collection and medical history. Participant race and ethnicity were self-reported in response to a question asked by the investigator. This information was captured in order to accurately describe the demographic characteristics of the study population. Participants were instructed to dose escalate over the first 4 weeks, starting with 0.6 mg once daily and increasing by 0.6 mg weekly until 3.0 mg was reached at week 5 (eFigure 1 in 